Your browser doesn't support javascript.
loading
Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group.
Teke, Kerem; Yilmaz, Hasan; Baltaci, Sümer; Akgül, Murat; Sahin, Bahadir; Türkeri, Levent; Bozkurt, Ozan; Yücetas, Ugur; Aslan, Güven; Bolat, Deniz; Izol, Volkan; Özkan, T Alp; Eskiçorapçi, Saadettin.
Afiliación
  • Teke K; Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey. Electronic address: drtekekerem@gmail.com.
  • Yilmaz H; Department of Urology, Kocaeli University School of Medicine, Kocaeli, Turkey.
  • Baltaci S; Department of Urology, Ankara University School of Medicine, Ankara, Turkey.
  • Akgül M; Department of Urology, Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Sahin B; Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
  • Türkeri L; Department of Urology, Acibadem M.A. Aydinlar University Altuzinade Hospital, Istanbul, Turkey.
  • Bozkurt O; Department of Urology, Dokuz Eylül Üniversitesi School of Medicine, Izmir, Turkey.
  • Yücetas U; Department of Urology, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Aslan G; Department of Urology, Dokuz Eylül Üniversitesi School of Medicine, Izmir, Turkey.
  • Bolat D; Department of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey.
  • Izol V; Department of Urology, Çukurova University School of Medicine, Adana, Turkey.
  • Özkan TA; Private Uro-Tip Uroloji Diagnosis Center, Kocaeli, Turkey.
  • Eskiçorapçi S; Department of Urology, Acibadem University, Istanbul, Turkey.
Urol Oncol ; 2024 Sep 30.
Article en En | MEDLINE | ID: mdl-39353827
ABSTRACT

OBJECTIVE:

To investigate the risk factors affecting cancer-specific survival (CSS) in nonresponsive disease to neoadjuvant chemotherapy (NAC) among patients with muscle-invasive bladder cancer (MIBC) who were treated with NAC and radical cystectomy (RC).

METHODS:

Patients with MIBC who underwent NAC and RC were retrospectively examined. By comparing clinical and pathological stages, patients whose pathological stage was lower than clinical stage were categorized as "NAC-responsive" and the remainder as "NAC-non-responsive." Apart from pathologic staging, variables compared between groups included age, gender, Eastern Cooperative Oncology Group (ECOG) score, clinical stages, NAC type and cycle number, durations between MIBC diagnosis and NAC initiation and RC, presence of hydronephrosis, number of lymph nodes removed, and variant histology of urothelial bladder cancer. CSS analysis was performed by construction of Kaplan-Meier survival curves and multivariable Cox regression was performed to identify the prognosticators in the NAC-non-responsive-group.

RESULTS:

Ninety-two patients were included with a mean age was 61.5 ± 8.5 years, of whom 84.8% were men. The NAC regimen used was predominantly gemcitabine-cisplatin (88%) and the median cycle number was 4. Fifty-six (60.9%) patients were NAC-non-responsive. There was a significantly lower proportion of patients receiving ≥4 cycles (46.4% vs. 66.7%) and a higher rate of patients with ECOG score ˃1 (33.9% vs. 11.1%) in the NAC-non-responsive-group compared to the NAC-responsive-group (both P < 0.05). Other variables were similar between groups. In multivariable analysis, only ypN+ was found to be an independent prognosticator for CSS in NAC-non-responsive-group (HR 2.725, CI95%1.017-7.303).

CONCLUSION:

Although higher ECOG scores and lower cycle numbers appears to be associated factors in NAC-non-responsive disease, only ypN(+) status was a prognosticator for CSS in this population.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Urol Oncol Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos